DANIEL MILAM: Open Payments
NPI 1568784205 · NASHVILLE, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$739 in 31 payments from 12 companies in 2025. Trend: 2023 $786 · 2024 $1,044 · 2025 $739
Food & beverage: $739
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 4 | $108 |
| GENZYME CORPORATION | 4 | $101 |
| AstraZeneca Pharmaceuticals LP | 4 | $88 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $73 |
| Grifols USA, LLC | 3 | $71 |
| United Therapeutics Corporation | 2 | $65 |
| Regeneron Healthcare Solutions, Inc. | 3 | $60 |
| Verona Pharma, Inc. | 2 | $59 |
| GlaxoSmithKline, LLC. | 2 | $39 |
| Viatris Specialty LLC | 2 | $38 |
Products named: DUPIXENT, FASENRA, Prolastin-C Liquid, Tyvaso, KEYTRUDA, Ohtuvayre, OFEV, TRELEGY ELLIPTA.
Industry payments across TN — which companies pay providers there.
